INVESTORS & MEDIA
Events & Presentations
Upcoming Events
Aug 12024 8:30 AM EDT
Aug 1, 2024 | 8:30 AM EDT
Archived Events
Jun 142024 10:30 AM EDT
Jun 14, 2024 | 10:30 AM EDT
The 2024 Annual Meeting of Shareholders of Regeneron Pharmaceuticals, Inc. will be held on Friday, June 14, 2024, commencing at 10:30 a.m., Eastern Time, virtually via the Internet at www.virtualshareholdermeeting.com/REGN2024.
Jun 112024 8:00 AM EDT
Jun 11, 2024 | 8:00 AM EDT
Jun 52024 8:30 AM EDT
Jun 5, 2024 | 8:30 AM EDT
May 142024 9:00 AM EDT
May 14, 2024 | 9:00 AM EDT
May 22024 8:30 AM EDT
May 2, 2024 | 8:30 AM EDT
Mar 132024 10:40 AM EDT
Mar 13, 2024 | 10:40 AM EDT
Mar 122024 11:15 AM EDT
Mar 12, 2024 | 11:15 AM EDT
Mar 62024 11:10 AM EST
Mar 6, 2024 | 11:10 AM EST
Feb 142024 1:20 PM EST
Feb 14, 2024 | 1:20 PM EST
Feb 22024 8:30 AM EST
Feb 2, 2024 | 8:30 AM EST
Jan 82024 5:15 PM EST
Jan 8, 2024 | 5:15 PM EST
Dec 142023 8:30 AM EST
Dec 14, 2023 | 8:30 AM EST
Nov 282023 8:30 AM EST
Nov 28, 2023 | 8:30 AM EST
Nov 152023 9:30 AM EST
Nov 15, 2023 | 9:30 AM EST
Nov 92023 11:00 AM EST
Nov 9, 2023 | 11:00 AM EST
Nov 82023 3:20 PM EST
Nov 8, 2023 | 3:20 PM EST
Nov 22023 8:30 AM EDT
Nov 2, 2023 | 8:30 AM EDT
Oct 52023
Oct 5, 2023
These slides contain the 60-week and 2-year (96-weeks) results from the Phase 3 PULSAR study of aflibercept 8 mg for nAMD. The presentation was given by Dr. Paolo Lanzetta at the 23rd EURETINA Congress on October 5, 2023.
Sep 112023 9:20 AM EDT
Sep 11, 2023 | 9:20 AM EDT
Sep 62023 8:45 AM EDT
Sep 6, 2023 | 8:45 AM EDT
Aug 32023 8:30 AM EDT
Aug 3, 2023 | 8:30 AM EDT
Jul 292023
Jul 29, 2023
These slides contain the 2-year (96 weeks) results from the Phase 2/3 PHOTON study of aflibercept 8 mg for DME. The presentation was given by Diana V. Do, MD at the American Society of Retina Specialists Annual Meeting on July 29, 2023.